On Monday, Citius Oncology announced the U.S. launch of Lymphir (denileukin diftitox-cxdl), the first FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) since 2018. Lymphir is an IL-2 receptor-directed fusion protein that kills cancer cells by binding to the IL-2 receptors found on the regulatory T-cells and releasing a toxin that inhibits protein…